Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Current Oncology · 03.04.2024 · 31 (4) · 1971-1993
DOI: 10.3390/curroncol31040148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.04.2024. Verfasst von Daniel Karel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Medical Oncology, The George Washington University, Washington, DC 20037, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic and molecular data. Specific genetic abnormalities, such as deletion of the long arm of chromosome 5 (del(5q)), TP53 inactivation and SF3B1 mutation, are increasingly associated with disease phenotype and outcome, as reflected in the recently updated fifth edition of the World Health Organization Classification of Hematolymphoid Tumors (WHO5) and the International Consensus Classification 2022 (ICC 2022) classification systems. Treatment of lower-risk MDS is primarily symptom directed to ameliorate cytopenias. Higher-risk disease warrants disease-directed therapy at diagnosis; however, the only possible cure is an allogenic bone marrow transplant. Novel treatments aimed at rational molecular and cellular pathway targets have yielded a number of candidate drugs over recent years; however few new approvals have been granted. With ongoing research, we hope to increasingly offer our MDS patients tailored therapeutic approaches, ultimately decreasing morbidity and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Medical Oncology, The George Washington University, Washington, DC 20037, USA.
- Department of Pathology, The George Washington University, Washington, DC 20037, USA.
- Department of Pathology, Washington DC VA Medical Center, Washington, DC 20422, USA.
- Department of Hematology/Medical Oncology, Washington DC VA Medical Center, Washington, DC 20422, USA.
ORCID-Profile: Victor E Nava
Zitieren
APA
Karel, D., Valburg, C., Woddor, N., Nava, V. E., & Aggarwal, A. (2024). Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Current Oncology, 31(4), 1971-1993. https://doi.org/10.3390/curroncol31040148
Vancouver
Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Current Oncology. 2024;31(4):1971-1993. doi:10.3390/curroncol31040148
BibTeX
@article{Karel2024,
author = {Karel, Daniel and Valburg, Claire and Woddor, Navitha and Nava, Victor E and Aggarwal, Anita},
title = {Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {4},
pages = {1971--1993},
doi = {10.3390/curroncol31040148}
}
EUVIMED